• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by argenx SE (Amendment)

    2/10/23 9:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email
    SC 13G/A 1 d443982dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Argenx SE

    (Name of Issuer)

    American Depositary Shares

    (Title of Class of Securities)

    04016X101

    (CUSIP Number)

    12/31/2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 04016X101    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Limited Partnership

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      2,226,549

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      2,615,415

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,615,415

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.7%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      IA

     


    CUSIP No. 04016X101    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Investments GP LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      2,226,549

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      2,615,415

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,615,415

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.7%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC

     


    CUSIP No. 04016X101    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Holdings LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      2,226,549

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      2,615,415

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,615,415

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.7%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC


    CUSIP No. 04016X101    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Asset Management Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      (a)  ☐        (b)  ☐

     

      Not Applicable

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      2,226,549

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      2,615,415

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,615,415

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.7%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC


    Item 1(a)

    Name of Issuer:

    Argenx SE

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    American Depositary Shares

     

    Item 2(e)

    CUSIP Number:

    04016X101

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 12/31/2022):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    2,615,415

     

      (b)

    Percent of class:

    4.7% (based on 55,395,856 shares outstanding as of 1/17/2023)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

     

      (ii)

    shared power to vote or to direct the vote: 2,226,549

     

      (iii)

    sole power to dispose or to direct the disposition of: None

     

      (iv)

    shared power to dispose or to direct the disposition of: 2,615,415

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 2/10/2023

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,
    for itself and as the general partner of
    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,
    for itself and as the general partner of
    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 2/10/2023 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.


    EXHIBIT 1

    JOINT FILING AGREEMENT

    The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached.

    Dated: 2/10/2023

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,
    for itself and as the general partner of
    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,
    for itself and as the general partner of
    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC
    Get the next $ARGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    7/8/2025Hold → Buy
    Deutsche Bank
    7/3/2025$700.00Overweight
    Morgan Stanley
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    3/17/2025Mkt Perform → Outperform
    Bernstein
    3/12/2025Sell → Hold
    Deutsche Bank
    1/17/2025Hold → Sell
    Deutsche Bank
    11/12/2024$697.00Peer Perform → Outperform
    Wolfe Research
    11/5/2024$715.00Sector Perform → Sector Outperform
    Scotiabank
    More analyst ratings

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • argenx upgraded by Deutsche Bank

      Deutsche Bank upgraded argenx from Hold to Buy

      7/8/25 8:21:40 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on argenx with a new price target

      Morgan Stanley resumed coverage of argenx with a rating of Overweight and set a new price target of $700.00

      7/3/25 7:49:10 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00

      5/13/25 8:50:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

      $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up

      7/31/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

      July 24, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium                32 800 50

      7/24/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

      Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (Mu

      6/30/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    SEC Filings

    See more
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      7/31/25 8:16:12 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      6/30/25 7:49:57 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      6/20/25 4:05:35 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/14/24 1:22:37 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/12/24 9:50:11 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by argenx SE (Amendment)

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      2/14/24 10:03:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Leadership Updates

    Live Leadership Updates

    See more
    • argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

      January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

      1/16/23 1:30:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Ana Cespedes to Board of Directors

      December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

      12/12/22 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Camilla Sylvest to Board of Directors

      September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg

      9/8/22 2:10:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Financials

    Live finance-specific insights

    See more
    • argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

      $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up

      7/31/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

      July 24, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium                32 800 50

      7/24/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care